【Molecular composition】：

【CAS】：184475-35-2

【source】：Gefitinib

【Certification】：CEP

【Spec】：FormⅠ

【DMF】：Available

【use】：

Gefitinib is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test